ABSTRACT Twelve patients with chronic severe asthma, having previously shown an FEV1 increase of less than 20% of the predicted value with prednisolone treatment (20-60 mg daily for 10 days), took part in a double blind crossover comparison of equipotent anti-inflammatory doses of betamethasone and prednisolone. Betamethasone (8 mg) and prednisolone (40 mg) were administered daily for 10 days with a washout period of 10 days between. In this first part of the study betamethasone was administered intramuscularly and prednisolone orally. Placebo injections and tablets were used. Mean FEV1 was not significantly different before each period. There was a significant increase in FEV1 while they were taking betamethasone but not prednisolone. Individual analysis of the data showed that FEV1 increased with betamethasone in nine patients and remained stable or decreased in three. During treatment with prednisolone baseline FEV1 increased moderately in three patients (FEV1 0-3, 0-5 and 0-6 1) and remained stable or decreased in nine. There was no significant difference between the bronchodilator responses to cumulative doses of inhaled salbutamol when they were measured immediately before, on the last day of treatment with each steroid, and between steroid treatment periods. The same protocol was followed four months later in five of the 12 patients but both drugs were administered orally on this occasion. Similar results were obtained. The greater effect of betamethasone on bronchial obstruction may be due to its longer biological half life or to some unidentified property of its metabolites. The bronchial response to inhaled 12 agonist appears not to be influenced by either steroid in these patients.
Introduction
Since the first observation by Carryer1 in 1952 of the dramatic effect of corticosteroid treatment in asthma, oral or injected corticosteroids have been prescribed extensively in the treatment of acute severe asthma, severe stable chronic asthma, and periods of worsening obstruction in asthmatic patients. 2 Indeed, some authors3 consider the reversibility of bronchoconstriction on these drugs as a compulsory criterion for the diagnosis of asthma. It has, however, been the experience of chest physicians that some patients with chronic asthma4 are totally or partially resistant to treatment with systemic prednisolone even in very high doses. There is little doubt about the diagnosis of asthma in these patients because clinical data usually fit the American Thoracic Society criteria5 and the airway obstruction is considerably improved by inhalation of bronchodilator drugs. Although these patients are rare, they are responsible for a noticeable percentage of admissions to hospital for asthma, because the course of the disease is generally severe owing to resistance to oral steroid treatment and resistance to some other drugs, such as cromoglycate and xanthine derivatives. 4 The major therapeutic benefits of corticosteroid treatment probably result from the suppression of inflammation and the facilitation of sympathetic nervous function. 6 Knowing that betamethasone and prednisolone have different anti-inflammatory effects,' we set out to determine whether betamethasone could alleviate airway obstruction in asthmatic patients showing partial resistance to prednisolone, and whether either corticosteroid could modify ,B-adrenergic function in these patients. 
Methods

EXPERIMENTAL DESIGN
We selected patients in whom FEV1 variation had never exceeded 20% of its predicted value during treatment with prednisolone in a dose ranging from 20 to 60 mg daily for at least 10 days, whenever prednisolone had been prescribed for exacerbations of their disease in the three previous years. Twelve patients entered the study, for whom four to 10 In the second part of the study five patients out of 12 (Nos 1, 4, 7, 9, 12), selected at random by the toss of a coin, followed a similar protocol but received the steroids in the reverse order from that used in the first trial; on this occasion both preparations were given orally in the form of powder made from crushed tablets. This second part of the study was performed on average 19 (SD 2) weeks after the first part.
After the study patients were seen on two more occasions, at two week intervals, for assessment of their clinical state and measurement of 8 am cortisol blood concentrations.
To ensure compliance with the treatment, patients were asked to bring back their drug packages. All of the patients had volunteered for previous studies and were well trained. All patients gave their informed consent to the study.
EXPERIMENTAL DETAILS
Oral or injected corticosteroids had not been prescribed in the month preceding the study; no patients received inhaled steroids. Bronchodilator drugs were avoided for at least 12 There was no difference in the initial functional indices (FEV1, FVC, PEF) between the two study periods. This study showed a significant effect of betamethasone but not of prednisolone on airway obstruction. Figure 2 gives individual and mean FEV1 before and after each period of steroid treatment. There was no significant difference between the initial FEV1 of the two periods; the FEV1 variation was significant (p < 0 05) (difference between post-treatment FEV1 and initial value) was significant after betamethasone (p < 0-05) but not after prednisolone. The order of administration of the drugs in the two groups did not influence the bronchial response to the drugs. Mean FEV1 was significantly higher after betamethasone than after prednisolone (p < 0.05). Figure 3 shows individual and mean FEV1 after inhalation of 1 mg salbutamol before and after each treatment period. There was no significant difference in FEV1 after salbutamol inhalation between the two The results of the second part of the study were similar to those of the first part. FEV1 increased significantly with betamethasone but not with prednisolone (fig 5 a) . Mean FEV1 after inhalation of I mg salbutamol was not significantly different before the two steroid periods; mean FEV1 after inhalation of salbutamol was greater after betamethasone treatment than it was before treatment (p < 0-05) but showed no significant difference after treatment with prednisolone (fig 5b) .
Prednisolone resistant asthma has been reported recently by Carmichael et al. 4 10 As in these studies, the course of the disease in our patients was severe, but no striking clinical features allowed discrimination from prednisolone sensitive patients. Resistance to steroids other than prednisolone has not been reported, but this may be due to more restricted use of these drugs.
Resistance to prednisolone is probably never complete and according to published criteria4 we selected patients known to have poor reversibility of airway obstruction with a high dose regimen of prednisolone. In these patients treatment with betamethasone resulted in a significant increase in FEV1, but treatment with prednisolone in equipotent antiinflammatory doses did not. Individual analysis of the data shows that during treatment with betamethasone FEV1 increased in all patients except one (No 8) . Betamethasone behaves as if it is a more potent steroid than prednisolone, although it may fail in some patients (No 8), which may be due perhaps to inadequate dosage or duration of treatment. In no patient did treatment with betamethasone succeed in completely alleviating airway obstruction, and mean FEV1 improvement after betamethasone in the 12 patients was less than 450 ml (fig 2) .
Individual analysis of the data of the three patients (3, 4, 1 1) who claimed to be in an unstable respiratory condition at the time of the study suggests that their better response to betamethasone might be due to poorer FEV1 before betamethasone than before prednisolone treatment. But the observed FEV1 variation with betamethasone (1-2, 0 78, and 1-04 1 respectively in the first part of the study and 0-58 1 for patient 4 in the second part of the study) was higher than the variation previously observed during prednisolone treatment in the same patients, when they were seen with even lower FEV1. Furthermore, there is striking evidence that FEV1 may deteriorate during prednisolone treatment (patients 4 and I 1), or that airway obstruction may not be completely alleviated by this drug whenever improvement is achieved by # agonists (patient 3), thus confirming the relative lack of efficacy of prednisolone in these patients.
The time course of the development of prednisolone resistance over months or years is not known. In our study five patients (1, 4, 7, 9, 12) showed an unchanged pattern of response to prednisolone and betamethasone after a mean period of four months as demonstrated in the second study, even though both drugs were administered in the reverse order from that of the first study.
Causes of resistance to prednisolone in man are not known. Development of resistance to glucocorticoid U-hormones has been attributed to synthesis of new proteins in animals'1 but it is not known whether steroid resistance is inherited or acquired in man. Impairment of normal steroid pharmacokinetics in man could produce prednisolone resistance. The route of administration, however, has no clinical relevance to prednisolone metabolism,12 13 and the systemic bioavailability of tablets is similar to that of intravenous aqueous-alcoholic solution. There is an equivalent absorption into the systemic circulation after administration of a given dose by the two routes.'4 Furthermore, the pharmacokinetic behaviour of prednisolone has been reported to be normal in asthmatic subjects. 5 Although we did not measure pharmacokinetic indices in our patients, there is no reason to suspect any defect in absorption or metabolism of prednisolone as no patients suffered from gut or liver disease. Furthermore, the pharmacokinetic behaviour of betamethasone is not affected by the route of administration,6 -19 provided that gastrointestinal function and liver function are both normal. The fact that both the oral and the intramuscular administration of the same dose of betamethasone elicited an alleviation of airway obstruction in our patients after an interval of four months gives further support to the contention that the route of administration has no relevance to the effect of the drug. A deficiency of receptors could not explain prednisolone resistance since in our patients steroid receptors were stimulated by betamethasone and since there is some evidence of normal steroid receptors in asthmatic patients. 20 Part of the action of corticosteroids on asthmatic bronchi may depend on inhibition of inflammatory response to immunological and non-immunological stimuli.2 We therefore matched dosages of betamethasone and prednisolone according to their reported anti-inflammatory properties. Antiinflammatory potency of various pure steroids has been estimated with different bioassays evaluating early and last phases of non-specific inflammation, but such relative potencies are not fixed ratios and vary considerably with the conditions of the bioassay used.7 Several different bioassays have been used, such as kaolin injection in rat pad, rat myocardial infarction, 21 and inhibition of hyaluronidase secre-22-bewe tion. This may explain why equipotency between betamethasone and prednisolone has been reported at dose ratios of 1:46 to 1:8.7 Although it may be argued that the dose ratio that we used in our study (1:5) might bias the results in favour of betamethasone, the similar FEV1 improvement obtained previously with either 30-40 mg or 50-60 mg of prednisolone (fig 1; offers indirect evidence that in our patients the dose of prednisolone was of little-imnportance and that the drug itself was generally inefficient.
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The difficulty of evaluating equipotent antiinflammatory doses of various corticosteroids is further complicated by the fact that the steroids available in clinical practice are steroid esters, whose anti-inflammatory effect may be different from that of pure steroids. Among prednisolone esters, only the anti-inflammatory potency of prednisolone steaglate has been evaluated to our knowledge, and it does not seem to be related to the molecular weight of the salt. 23 Although the doses we used are in the range of reported equipotent doses for betamethasone and prednisolone, their bronchial effects on the components of airway inflammation were different. The better bronchial effect of betamethasone than prednisolone may be due to the longer biological half life of betamethasone (36 versus 8 hours). Steroid dosage and timing of the doses have some relevance in chronic asthma.
Another possible hypothesis is that the cellular metabolism of betamethasone might differ from that of prednisolone or that one of betamethasone's metabolites might exert a potent anti-inflammatory effect. Neither hypothesis has been investigated to our knowledge.
The increase in FEV, after inhalation of salbutamol was quite large in our patients. Even after betamethasone, however, the response to salbutamol was not modified. This is in contrast to usual experience in severe asthma, in which steroids are administered to facilitate sympathetic nervous function,6 and it contrasts with in vitro observations that corticosteroids enhance secretion of cyclic AMP after ,B receptor stimulation.24 Pathological investigations in acute severe asthma, however, show diffuse mucus plugging of bronchioles,25 which may inhibit penetration of inhaled bronchodilators. Our patients did not display the acute dyspnoea syndrome or acute severe asthma, but had severe chronic obstruction. Bronchial changes may therefore have been different from those of acute severe asthma and airway permeability may have been at least partially preserved.
The increase of FEV1 after inhalation of salbutamol cannot be attributed to a ceiling effect of bronchodilatation since none of our patients reached 100% of the predicted FEV1 with steroid treatment alone. After inhaling salbutamol two patients (3 and 10) reached 94% and 83% of the predicted FEV1. Although these patients were good responders to salbutamol, which justified the long term prescription of bronchodilators that we started in these patietns, the severity of their disease was more related to the rapid recurrence of bronchial obstruction when the effect of the 2 agonist had vanished after a few hours, and this could have been a consequence of the severe inflammatory course of their disease.
